However, the failure to fully prevent tau-mediated LTD facilitation by etanercept indicates the possibility that other molecular mechanisms are also involved in Alzheimer’s disease-related tau-enhanced LTD. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.